Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visual field loss associated with vigabatrin: quantification and relation to dosage.

P Hardus1, W M Verduin, M Engelsman

  • 1Departments of Ophthalmology, Academic Hospital Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. p.l.l.j.hardus@ohk.azg.nl

Epilepsia
|March 10, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Body Composition on Surgical Outcome in Rectal Cancer Patients, a Retrospective Cohort Study.

World journal of surgery·2019
Same author

Dexa Body Composition Assessment in 10-11 Year Healthy Children.

PloS one·2016
Same author

The rationale for intensity-modulated proton therapy in geometrically challenging cases.

Physics in medicine and biology·2013
Same author

Infectious uveitis: recent advances in diagnosis and treatment.

Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH·2012
Same author

Prevention of ocular firework injuries.

Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH·2012
Same author

Dried blood spots: a new tool for tuberculosis treatment optimization.

Current pharmaceutical design·2011

The total amount of vigabatrin (VGB) medication is linked to visual field loss in epilepsy patients. Men showed greater impact, and VGB should be a last resort treatment.

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Pharmacology

Background:

  • Vigabatrin (VGB) is an antiepileptic drug used to treat certain types of seizures.
  • Visual field defects are a known potential side effect of VGB therapy.
  • Understanding the dose-response relationship is crucial for patient safety.

Purpose of the Study:

  • To investigate the correlation between vigabatrin (VGB) dosage, duration, and total exposure with the extent of visual field loss.
  • To assess the influence of co-medications and patient compliance on VGB-induced visual field deficits.

Main Methods:

  • Ninety-two epilepsy patients with current or past VGB use were evaluated using Goldmann perimetry.
  • Visual field loss was quantified using the Esterman grid and a novel percentage surface loss method.

Related Experiment Videos

  • Drug history, including VGB and concomitant antiepileptic drugs (AEDs), was meticulously recorded; serum AED levels were determined.

    • Main Results:

    • The total amount of VGB administered was the strongest predictor of visual field loss (p < 0.001).
    • Male patients exhibited a significantly higher degree of visual field impairment compared to female patients (p = 0.026).
    • Patient compliance was high, and co-administered AEDs did not significantly affect the observed visual field changes.

    Conclusions:

    • Prolonged vigabatrin (VGB) use is significantly correlated with the severity of visual field loss.
    • VGB should be reserved for cases where alternative treatments are ineffective.
    • Pre-treatment and regular 6-monthly peripheral visual field examinations are recommended for patients on VGB therapy.